跳至主要内容
临床试验/NCT00921362
NCT00921362已完成不适用

Seroquel (Quetiapine Fumarate) InPractice Evaluation Programme

AstraZeneca0 个研究点目标入组 1,387 人开始时间: 2006年5月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
AstraZeneca
入组人数
1,387
主要终点
Brief Psychiatric Rating Scale - BPRS

研究概览

简要总结

Patients eligible for entry into the study have a diagnosis of schizophrenia defined by Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) criteria and of a chronic or sub-chronic nature.The primary purpose of the study is to observe symptoms changes over 6 months in schizophrenia in patients treated with Seroquel; additionally disease severity and treatment compliance are followed

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • To assess at baseline and after treatment administration the severity of the illness in patients with schizophrenia, using the scores obtained after the application of the CGI scale
  • To assess the changes in symptoms of patients treated with Seroquel for 24 weeks, using BPRS (Brief Psychiatry Rating Scale) as measuring tool

排除标准

  • All the patients who have a known hypersensitivity to Seroquel /quetiapine or any of its excipients will not be included in this study.

结局指标

主要结局

Brief Psychiatric Rating Scale - BPRS

时间窗: Monthly at every clinic visit- 7 times

次要结局

  • Clinical Global Impression Severity of Illness(Monthly/ at every clinic visit-7 times)
  • CGI-S Clinical Global Impression Improvement CGI -I(Monthly/ at every clinic visit except first visit- 6 times)

研究者

发起方
AstraZeneca
申办方类型
Industry

相似试验